US 11479771
Antisense oligonucleotides for the treatment of eye disease
granted A61KA61K31/7088A61K31/712
Quick answer
US patent 11479771 (Antisense oligonucleotides for the treatment of eye disease) held by ProQR Therapeutics II B.V. expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/7088, A61K31/712, A61P, A61P27/02